Date: 2011-12-23
Type of information: Grant
Company: Tigenix (Belgium)
Investors:
Amount: € 2.9 million
Funding type: grant
Planned used: The grant will support the development of its Cx611 program of allogeneic expanded adipose derived stem cells for the treatment of rheumatoid arthritis.
Others: TiGenix has announced that as the coordinator of the international consortium REGENER-AR it has obtained a substantial grant from the European Seventh Framework Programme (FP7). The consortium includes 10 partners from Spain, France, the UK, the Netherlands and Belgium, and consists of a combination of top-level research institutes, medical entities and biotech companies. REGENER-AR will receive a total of € 5.9 million, of which € 2.9 million is allocated to TiGenix and Cellerix, its Spanish subsidiary, to fund research and clinical development of Cx611. In addition, the grant covers the cost of preclinical studies performed by members of the consortium to improve the understanding of the disease modifying activity of Cx611, which will further reduce its R&D expenses related to these studies.
Therapeutic area: Regenerative medicine
